Evidence map›Paper›PMID 34723035›Full record

ArticleACS omega2021

Synthesis and Biological Evaluation of a c(RGDyK) Peptide Conjugate of SRPIN803.

George Leonidis, Panagiotis Dalezis, Dimitrios Trafalis, Dimitris Beis, Panagiota Giardoglou, Anastasia Koukiali, Ioanna Sigala, Eleni Nikolakaki, Vasiliki Sarli

Open access · goldAbstract read
In one paragraph

Article in ACS omega, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

George LeonidisDepartment of Chemistry, Aristotle University of Thessaloniki, University Campus, 54124 Thessaloniki, Greece.
Panagiotis DalezisLaboratory of Pharmacology, Medical School National and Kapodistrian University of Athens, 75 Mikras Asias Street, Athens 11527, Greece.
Dimitrios TrafalisLaboratory of Pharmacology, Medical School National and Kapodistrian University of Athens, 75 Mikras Asias Street, Athens 11527, Greece.
Dimitris BeisZebrafish Disease Model Lab, Biomedical Research Foundation Academy of Athens, Athens 115 27, Greece.ORCID https://orcid.org/0000-0003-2579-7848
Panagiota GiardoglouZebrafish Disease Model Lab, Biomedical Research Foundation Academy of Athens, Athens 115 27, Greece.
Anastasia KoukialiDepartment of Chemistry, Aristotle University of Thessaloniki, University Campus, 54124 Thessaloniki, Greece.
Ioanna SigalaDepartment of Chemistry, Aristotle University of Thessaloniki, University Campus, 54124 Thessaloniki, Greece.
Eleni NikolakakiDepartment of Chemistry, Aristotle University of Thessaloniki, University Campus, 54124 Thessaloniki, Greece.
Vasiliki SarliDepartment of Chemistry, Aristotle University of Thessaloniki, University Campus, 54124 Thessaloniki, Greece.ORCID https://orcid.org/0000-0002-6128-8277
Aristotle University of Thessaloniki · GRAcademy of Athens · GRNational and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the present study, SRPIN803 and c(RGDyK)-SRPIN803 hybrid compounds were efficiently synthesized and evaluated for their stability in human plasma and buffers of pH 7.4 and 5.2. The hybrids were mainly cytostatic against a panel of tested cancer cells, whereas one c(RGDyK)-SRPIN803 hybrid, geo35, was the most active compound in this screen and was cytotoxic against cell lines MCF7 and MRC5 with IC

Identifiers

PMID34723035
PMCPMC8552469
OpenAlexW3205656162

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.